uveal melanoma – Medxy AI

葡萄膜黑色素瘤的15-GEP/PRAME检测预后价值：有无确认性细胞病理学的比较

Prognostic Value of 15-GEP/PRAME Assay With or Without Confirmatory Cytopathology in Uveal Melanoma: Insights From the Collaborative Ocular Oncology Group Study 2

By MedXY 10/20/2026

This study validates the prognostic accuracy of the 15-gene expression profiling (15-GEP) and PRAME assay in uveal melanoma patients irrespective of confirmatory cytopathology, supporting its use in clinical management when cytopathology is unavailable.

news Oncology Ophthalmology

Impact of Ocular Proton Therapy on Corneal Subbasal Nerve Plexus in Uveal Melanoma: Longitudinal Confocal Microscopy Findings

By MedXY 10/08/2026

Ocular proton therapy causes significant decreases in corneal nerve fiber parameters in uveal melanoma patients, with partial recovery by 12 months and minimal changes in corneal sensitivity and patient-reported outcomes.

news Oncology Ophthalmology

One-Year Tumor Volume Regression as a Predictor of Survival in I-125 Plaque Brachytherapy for Posterior Uveal Melanoma

By MedXY 08/04/2026

Tumor volume regression at one year post-I-125 plaque brachytherapy significantly predicts overall survival in posterior uveal melanoma, with intermediate regression showing the best outcomes.

news Oncology Ophthalmology

MBD4 Germline Variants Mark a Strong Predisposition to Uveal Melanoma, Supporting Broad Genetic Screening

By MedXY 05/04/2026

A large French case series found pathogenic or likely pathogenic germline MBD4 variants in 23 of 896 patients with uveal melanoma, corresponding to a 31-fold relative risk versus the general population.